Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.42 |
| ▸ | ACACA | Q13085 | 4/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30893002 | 1.00 | ACACB (0.42) | ACACBACACAPBKCCRL2CKS1B | |
| SCHEMBL27213902 | 0.86 | HDAC4 (0.44) | CNR2HDAC4HDAC6LMNAGAA | |
| SCHEMBL27231174 | 0.86 | HDAC4 (0.44) | CNR2HDAC4HDAC6LMNAGAA | |
| SCHEMBL30849245 | 0.85 | GAA (0.41) | CNR2HDAC4HDAC6LMNAGAA | |
| SCHEMBL14450215 | 0.83 | ACACB (0.42) | ACACBACACAPBKCKS1BSKP1 | |
| SCHEMBL27230956 | 0.79 | HDAC4 (0.46) | CNR2HDAC4HDAC6 | |
| SCHEMBL27213729 | 0.79 | HDAC4 (0.46) | CNR2HDAC4HDAC6 | |
| SCHEMBL8252188 | 0.79 | ACACB (0.48) | ACACBACACAPBKCKS1BSKP1 | |
| SCHEMBL29318688 | 0.77 | HDAC4 (0.41) | CNR2HDAC4HDAC6 | |
| SCHEMBL27395308 | 0.77 | HDAC4 (0.41) | CNR2HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | ACACB 59/4885ACACA 149/4885PBK 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.